Literature DB >> 28088123

Antibody-dependent cellular cytotoxicity and influenza virus.

Hillary A Vanderven1, Sinthujan Jegaskanda1, Adam K Wheatley1, Stephen J Kent2.   

Abstract

Antibodies are a key defence against influenza infection and disease, but neutralizing antibodies are often strain-specific and of limited utility against divergent or pandemic viruses. There is now considerable evidence that influenza-specific antibodies with Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), can assist in the clearance of influenza infection in vitro and in animal models. Further, ADCC-mediating antibodies that recognize a broad array of influenza strains are common in humans, likely as a result of being regularly exposed to influenza infections. The concept that influenza-specific ADCC can assist in the partial control of influenza infections in humans is gaining momentum. This review examines the utility of influenza-specific ADCC antibodies.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28088123     DOI: 10.1016/j.coviro.2016.12.002

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  36 in total

1.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

Review 2.  Defining the role of NK cells during dengue virus infection.

Authors:  Anuja Mathew
Journal:  Immunology       Date:  2018-03-23       Impact factor: 7.397

3.  Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.

Authors:  Carolyn M Boudreau; Wen-Han Yu; Todd J Suscovich; H Keipp Talbot; Kathryn M Edwards; Galit Alter
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 4.  Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection.

Authors:  Ivayla E Gyurova; Ayad Ali; Stephen N Waggoner
Journal:  Viral Immunol       Date:  2019-12-03       Impact factor: 2.257

Review 5.  The Multifaceted B Cell Response to Influenza Virus.

Authors:  Jonathan H Lam; Nicole Baumgarth
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

6.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

7.  Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.

Authors:  Yawei Ni; Jianhua Guo; Debra Turner; Ian Tizard
Journal:  Vaccine       Date:  2017-11-06       Impact factor: 3.641

8.  Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.

Authors:  Kelsey Florek; James Mutschler; Huong Q McLean; Jennifer P King; Brendan Flannery; Edward A Belongia; Thomas C Friedrich
Journal:  Vaccine       Date:  2019-11-18       Impact factor: 3.641

9.  Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.

Authors:  Eugenio J Abente; Daniela S Rajao; Jefferson Santos; Bryan S Kaplan; Tracy L Nicholson; Susan L Brockmeier; Phillip C Gauger; Daniel R Perez; Amy L Vincent
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

10.  Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay.

Authors:  Xuemin Chen; Larry J Anderson; Christina A Rostad; Lingmei Ding; Lilin Lai; Mark Mulligan; Nadine Rouphael; Muktha S Natrajan; Courtney McCracken; Evan J Anderson
Journal:  J Immunol Methods       Date:  2020-10-16       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.